News | April 15, 2026
FDA presses 2,200+ companies to fix missing clinical trial results
Move amid evidence of widespread reporting gaps
Move amid evidence of widespread reporting gaps
The programme features headline data from pivotal Phase III trials, including PREVAIL in gMG, KOMET in NF1-PN, and CHAMPION-NMOSD, alongside real-world evidence supporting established therapies
CRDMO plans to add 800–1,000 women across scientific and leadership roles over three years
Backed by funding from an NIHR Doctoral Award, the guidance is focused on spotting abdominal tumours
Scientists at the forum warned of an increasingly volatile health landscape
The study’s multi-technology design is intended to improve reproducibility, strengthen regulatory-grade evidence generation
Workshop on ECG interpretation also marks launch of “Handbook on ECGs – Volume 2”
Policy, regulations, AI and CRDMO take centre stage at the flagship event of the Department of Pharmaceuticals
At India Pharma 2026, Dr Bahl calls for experimentation over imitation as funding rises and translational ecosystem reforms gather pace
Veteran biopharma leader stressed that generic medicines must be viewed separately from biologics
Subscribe To Our Newsletter & Stay Updated
